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Abstract
Fibroblast growth factor-1 (FGF1) and FGF2 play a critical role in angiogenesis, a formation of new blood vessels from
existing blood vessels. Integrins are critically involved in FGF signaling through crosstalk. We previously reported that FGF1
directly binds to integrin avb3 and induces FGF receptor-1 (FGFR1)-FGF1-integrin avb3 ternary complex. We previously
generated an integrin binding defective FGF1 mutant (Arg-50 to Glu, R50E). R50E is defective in inducing ternary complex
formation, cell proliferation, and cell migration, and suppresses FGF signaling induced by WT FGF1 (a dominant-negative
effect) in vitro. These findings suggest that FGFR and avb3 crosstalk through direct integrin binding to FGF, and that R50E
acts as an antagonist to FGFR. We studied if R50E suppresses tumorigenesis and angiogenesis. Here we describe that R50E
suppressed tumor growth in vivo while WT FGF1 enhanced it using cancer cells that stably express WT FGF1 or R50E. Since
R50E did not affect proliferation of cancer cells in vitro, we hypothesized that R50E suppressed tumorigenesis indirectly
through suppressing angiogenesis. We thus studied the effect of R50E on angiogenesis in several angiogenesis models. We
found that excess R50E suppressed FGF1-induced migration and tube formation of endothelial cells, FGF1-induced
angiogenesis in matrigel plug assays, and the outgrowth of cells in aorta ring assays. Excess R50E suppressed FGF1-induced
angiogenesis in chick embryo chorioallantoic membrane (CAM) assays. Interestingly, excess R50E suppressed FGF2-induced
angiogenesis in CAM assays as well, suggesting that R50E may uniquely suppress signaling from other members of the FGF
family. Taken together, our results suggest that R50E suppresses angiogenesis induced by FGF1 or FGF2, and thereby
indirectly suppresses tumorigenesis, in addition to its possible direct effect on tumor cell proliferation in vivo. We propose
that R50E has potential as an anti-cancer and anti-angiogenesis therapeutic agent (‘‘FGF1 decoy’’).
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Introduction
The FGF family consists of 22 related polypeptides that are
expressed in almost all tissues and are multifunctional. They can
be subdivided in canonical (cFGFs, FGF7-10, FGF16-20, FGF22),
intracellular (iFGFs, FGF11-14), and hormonelike (hFGFs,
FGF19, 21 and 23) subfamilies [1]. Some FGFs, like FGF1 and
FGF2, have potent angiogenic activity and are implicated as
promoters of angiogenesis, the formation of new blood vessels, in
cancer and chronic inflammatory diseases. FGFs also increase the
motility and invasiveness of a variety of cell types [2–4]. The
biological effects of FGFs are mediated by four structurally related
receptor tyrosine kinases: FGFR1, FGFR2, FGFR3, and FGFR4.
The binding of FGF to its receptor results in receptor dimerization
and subsequent transphosphorylation of specific tyrosine residues
within the cytoplasmic domain. This leads to the activation of
intracellular signaling cascades. The four main signaling pathways
downstream of receptor activation are 1) the Janus kinase/signal
transducer and activator of transcription (Jak/Stat), 2) phosphoi-
nositide phospholipase C (PLCc), 3) phosphatidylinositol 3-kinase
(PI3K), and 4) mitogen-activated protein kinase/extracellular
signal-regulated kinase (MAPK/Erk). [2–4]. FGF1 binds to all
known cell-surface FGFR isoforms (FGFR1b, 1c, 2b, 2c, 3b, 3c,
and 4) [2–4].
FGFs are potent mitogens for many cancer cells. More than
80% of prostate cancer cells express FGF8, and the levels of FGF8
expression correlate with the levels of invasiveness [5]. In breast
cancer cells, cells that overexpress FGF1 or FGF4 grow faster than
cells with low FGF expression in vivo [6]. The levels of FGFR
expression also correlate with the invasiveness of cancer [7].
FGF1/FGFR1 signaling (both autocrine and paracrine loops) thus
plays a critical role in cancer progression. Because FGF signaling
enhances multiple biological processes that promote tumor
progression, it is an attractive therapeutic target, particularly since
therapies targeting FGF receptors and/or FGF signaling may
affect both the growth of tumor cells and angiogenesis. FGF plays
a role in pathological angiogenesis in inflammatory diseases.
Transient exposure to FGF1 upregulates the expression of the cell
adhesion molecules ICAM (intercellular adhesion molecule)-1 and
VCAM (vascular cell adhesion molecule)-1 in endothelial cells and
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increases polymorphonuclear leukocyte adhesion and transen-
dothelial migration [8].
Integrins are a family of cell adhesion receptors that recognize
extracellular matrix ligands and cell surface ligands [9]. Integrins
are transmembrane a2b heterodimers, and at least 18 a and 8
b subunits are known [10]. Integrins are involved in signal
transduction upon ligand binding and their functions are in turn
regulated by signals from within the cell [10]. Crosstalk between
integrins and growth factor receptors are an important signaling
mechanism during normal development and pathological pro-
cesses [11]. We previously reported that FGFR and integrins
crosstalk through direct integrin binding to FGF [12]. We first
predicted that FGF1 binds to integrin avb3 using docking
simulation. We found that FGF1 directly binds to integrin avb3
(KD about 1 mM) [12]. Antagonists to avb3 (mAb 7E3 and cyclic
RGDfV) block this interaction. The CYDMKTTC sequence (the
specificity loop) within the ligand-binding site of b3 plays a role in
FGF1 binding, suggesting that FGF1 binds to a binding site
common to other avb3 ligands. The integrin binding site in FGF1
is distinct from the FGFR-binding site. We identified an FGF1
mutant (R50E) that is defective in integrin binding but still binds to
heparin and FGFR. R50E is defective in inducing DNA synthesis,
cell proliferation, cell migration, and chemotaxis, suggesting that
the direct integrin binding to FGF1 is critical for FGF signaling.
WT FGF1 induces both transient (within 3 hours of stimulation)
and sustained activation of ERK1/2 (after 3 hours of stimulation)
in NIH3T3 cells. In contrast, R50E is defective in inducing
sustained ERK1/2 activation while it induces transient ERK1/2
activation. R50E induces transient activation but is defective in
sustained activation of FGFR1 and FRS2a as well [13].
Importantly, WT FGF1 induces ternary complex formation
(integrin-FGF-FGFR1) but R50E is defective in this function
[13]. We propose a model in which integrin and FGFR bind to
FGF1 simultaneously and make a ternary complex on the cell
surface. Our model predicts that the R50E mutant should
compete with WT FGF1 for binding to integrins. Thus, R50E
should be antagonistic. We discovered that R50E is actually
a dominant-negative mutant of FGF1 in vitro. Excess R50E
suppresses DNA synthesis and cell proliferation induced by WT
FGF1 [13].
Taken together, our previous results suggest that 1) Ternary
complex formation is involved in FGF signaling, 2) the defect of
R50E to bind to integrin may be directly related to the functional
defective of R50E, and 3) R50E is a dominant-negative mutant.
These results suggest that R50E has potential as a therapeutic in
cancer [13]. These results suggest that R50E has translational
potential: R50E can be an anti-angiogenesis and anti-cancer
therapeutic. To address this hypothesis, in the present study, we
studied the effect of R50E on angiogenesis and tumorigenesis.
Materials and Methods
All chemicals were purchased from Sigma (St. Louis, MO) or
Nacalai tesque (Kyoto, Japan) unless otherwise stated. Wild-type
FGF (WT) and mutant form FGF (R50E) were bacterially
expressed and purified as described previously [12]. HRP-
conjugated anti-His tag antibody was purchased from Qiagen
(Valencia, CA). Human umbilical endothelial cells (HUVEC) were
purchased from Sanko-junyaku (Tokyo, Japan) and were routinely
cultured in EGM-2 Bullet kit (Lonza Basel, Switzerland)
supplemented with 2% FCS. DLD-1 human colon carcinoma
cells were obtained from American Type Culture Collection
(ATCC) and were maintained in RPMI1640 supplemented with
10% FCS and antibiotics.
Generation of DLD-1 Colon Carcinoma Cells that Secrete
WT or R50E FGF1 and Tumorigenesis in vivo
We inserted the 6-His and S tags in the Kpn I/Bam HI site in
pSecTag vector as described [14] and inserted WT or mutant
FGF1 cDNA fragment (Bgl II/Bam HI fragment) into the Bam HI
site of the vector. We transfected the pSecTag construct encoding
WT or mutant FGF1 to DLD-1 cells, and selected for zeocin
resistance. We detected the secretion of WT and R50E mutant in
DLD-1 cells by concentrating the culture medium (15X) using
ulrafiltration and by Western blotting with HRP-labeled anti-6His
antibodies. These cells were subcutaneously injected into nude
mice (106 cells/mouse) without further cloning or enrichment. The
tumor growth was monitored using caliper, and tumor volume (v)
was calculated as described [15].
Cell Migration
A polycarbonate filter of 8 mm pore size of the transwell insert
was used to test cell Migration. Lower side of the filter was coated
with 10 mg/ml fibronectin (Asahi Glass, Tokyo) for 1 h at room
temperature. After washing, the insert was placed into a 24-well
cell culture plate, and the lower portion of the plate was filled with
600 ml of serum-free EBM-2 medium containing 5 ng/ml WT
FGF1 or the mixture of WT FGF1 (5 ng/ml) and R50E (250 ng/
ml) in the presence of 5 mg/ml heparin. HUVEC cells (66104
cells/filter) were plated on the filter and incubated at 37uC for 6 h,
and cells were visualized by crystal violet staining. The uncoated
upper side of each filter was wiped with a cotton swab to remove
cells that had not migrated through the filter. Chemotaxed cells
were counted from the digital images of the stained cells. Results
are expressed as means 6 S.E. of the cell number.
Endothelial Cell Tube Formation
Serum starved HUVECs were plated in wells (36104 cells/well)
of 48 well plate coated with 150 ml Matrigel (BD Biosciences, San
Jose, CA) in serum-free EBM-2 medium. The medium contains
5 ng/ml WT FGF1, or the mixture of WT FGF1 (5 ng/ml) and
R50E (250 ng/ml) in the presence of 5 mg/ml heparin. Cells were
incubated for 8 h at 37uC. Images were observed under Nikon
Eclipse TE2000E inverted microscope with 46 objective lens
(Nikon). The Number of vessel branch points of tube per field was
counted from the digital images. Results are expressed as means 6
S.E. of the numbers of vessel branch points.
Matrigel Plug Assay
Matrigel plugs containing 1 mg/ml FGF-WT, 1 mg/ml FGF-
R50E, or the mixture of 1 mg/ml WT FGF1 and 50 mg/ml FGF-
R50E were prepared on ice. The plugs (1 ml each) were injected
subcutaneously into the back of 12 weeks old SD rat. The matrigel
plugs were removed 10 days after injection, fixed with formalin,
and embedded in paraffin block. Tissue sections were stained with
antibodies against von Willebrand factor (Dako Glostrup, Den-
mark), a blood vessel marker. The number of blood vessels was
counted in 5 independent areas of a section under a light
microscope. Results are expressed as means 6 S.E. of the stained
cell number.
Rat Aorta Ring Assay
Culturing of aortic explants in three-dimensional collagen gel
was performed as described [16]. Briefly, thoracic aortas were
removed from 6 weeks old Sprague-Dawley (SD) rat. The
periaortic fibroadipose tissue was carefully removed and sectioned
at approximately 1 mm thickness. Cellmatrix porcine type I
collagen (3 mg/ml) (Nitta gelatin) was gelled in 24 well plate at
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37uC for 30 min. Ring shaped aortas were embedded in the gels
and immersed in medium containing 50 ng/ml WT FGF1,
50 ng/ml R50E, or the mixture of WT and R50E (50 ng/ml
and 2.5 mg/ml) and incubated at 37uC for 10 days. Media were
changed every day. The spatial distributions of microvessel sprouts
were observed using phase-contrast inverted microscope with
digital camera.
Chick Embryo Chorioallantoic Membrane (CAM) Assay
CAM assays were performed as previously described [17,18].
Briefly, fertilized chick eggs were grown in a rotating humidified
incubator for 11 days until blood vessels fully developed. We then
created a window in the eggshell to expose the underlying
chorioallantoic membrane. After securing the eggs in the
horizontal position, we placed 6 mm filter discs filled with saline
or saline+FGF directly over a vessel within the membrane. The
eggs were incubated for another 2 days. At day 13 we excised the
membrane surrounding the filter and captured a digital image
(using MoticImage software) to count the total number of vessel
branch points directly beneath the disc.
Other Method
MTS assays were performed as described [19].
Statistical Analysis
Statistical analysis was performed using Prism software
(GraphPad software).
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health,
University of California Davis, and Osaka University. Protocols
were approved by University of California Davis Institutional
Animal Care and Use Committee and the Animal Experiment
Committee of Osaka University.
Results
Suppression of Tumorigenesis in vivo by R50E
We have reported that FGF1 specifically binds to integrin avb3
[12]. The FGF1 mutant (R50E) is defective in integrin binding but
still binds to heparin and FGFR. R50E is defective in inducing
DNA synthesis, cell proliferation, cell migration, and chemotaxis,
suggesting that the direct integrin binding to FGF1 is critical for
FGF signaling [12]. WT FGF1 induces ternary complex formation
(integrin-FGF1-FGFR1) in NIH3T3 cells and human umbilical
endothelial cells (HUVECs), but R50E is defective in these
functions. WT FGF1 induces sustained activation of ERK1/2, but
R50E is defective in this function. Notably excess R50E suppresses
signals induced by WT FGF1 in vitro. Our results suggest that 1)
R50E is a dominant-negative mutant, 2) ternary complex
formation is involved in FGF signaling, and 3) the defect of
R50E to bind to integrin may be directly related to the
antagonistic action of R50E. Taken together, these results suggest
that R50E has potential as a therapeutic in cancer [13].
To test if R50E may act as an antagonist to FGF signaling
in vivo, we stably expressed R50E or WT FGF1 in a secretion
vector in DLD-1 colon carcinoma cells, and tested if R50E affects
tumor growth in vivo. These cells secreted 6His-tagged R50E or
WT FGF1 into culture medium (Fig. 1a). The expression of WT
FGF1 or R50E had little or no effect on cell survival in vitro in the
presence of FCS (Fig. 1b). The expression of WT FGF1
significantly enhanced cell survival in the absence of serum, but
the expression of R50E did not (Fig. 1c). When the population of
DLD-1 colon cancer cells that stably express WT FGF1 or R50E
were injected subcutaneously into nude mice (1 million cells/site,
two sites per mouse), cells that secrete WT FGF1 generated bigger
tumors (n = 8) but cells that secrete R50E generated smaller
tumors (n = 8) than mock-transfected cells (n = 7) (Fig. 1d and 1e).
These results suggest that R50E suppressed tumorigenesis in vivo
while WT FGF1 markedly enhanced it. Since R50E did not affect
tumor cell proliferation or survival in vitro, it is likely that R50E
suppressed tumorigenesis in vivo indirectly through blocking FGF
signaling in endothelial cells (angiogenesis) or stromal cells. We
thus tested the effect of R50E on angiogenesis.
R50E Suppresses WT FGF-1 Induced Endothelial Cell
Migration
Endothelial cell migration is a critical feature of tumor
angiogenesis. We tested the effect of R50E on migration of
HUVECs. Lower side of the filter in the modified Boyden
chamber was coated with fibronectin (10 mg/ml). The lower
chamber was filled with serum-free EBM-2 medium with WT
FGF1 (5 ng/ml) and/or R50E (5 and 250 ng/ml, respectively).
HUVECs were plated on the filter and incubated for 6 h, and cells
were stained with crystal violet. Chemotaxed cells were counted
from the digital images of the stained cells. We found that R50E
did not induce cell migration at 5 and 250 ng/ml concentration
(Fig. 2). Excess R50E significantly suppressed migration of
HUVECs induced by WT FGF1 (Fig. 2). This suggests that
R50E acts as an antagonist of FGF1 in migration of HUVECs.
R50E Suppresses WT FGF1 Induced Tube Formation of
Endothelial Cells
One of the most specific tests for angiogenesis is the
measurement of the ability of endothelial cells to form three-
dimensional structures (tube formation) [20]. Endothelial cells of
all origins appear to be able to form tubules in vitro on
extracellular matrix components. We examined the effect of
R50E on the tube formation of HUVECs in vitro. We plated
serum-starved HUVECs on reconstituted extracellular matrix
(Matrigel, growth factor reduced)-coated plates, and incubated
with WT FGF1 and/or R50E (5 and 250 ng/ml, respectively) for
8 h. We counted the number of branching points per field from
the digital images. We found that WT FGF1 markedly enhanced
tube formation and R50E (5 ng/ml) did not induce tube
formation. High dose R50E weakly induced tube formation.
Excess R50E (250 ng/ml) significantly suppressed tube formation
induced by WT FGF1 (Fig. 3). This suggests that R50E directly
affects endothelial cell and competes with WT FGF1 for its
binding to integrin to generate tube-like structure.
R50E Suppresses Angiogenesis in the Rat Aorta Ring
Assays
To test the effect of R50E on angiogenesis in more physiological
conditions, we performed an aorta ring assay. This organ culture
assay uniquely recapitulates the key steps in the process such as
matrix degradation, migration, proliferation, and reorganization
while other in vitro assays are designed to study a particular step in
the angiogenesis. Isolated rat aortic ring was embedded in collagen
gels in DMEM containing WT FGF1, R50E, or the mixture of
WT FGF1 and excess R50E and cultured for 10 days. WT FGF1
(50 ng/ml) markedly induced the outgrowth of cells from aortic
arch, but R50E (50 ng/ml) did not (Fig. 4). Excess R50E
(2500 ng/ml) significantly suppressed the outgrowth of cells
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Figure 1. R50E suppresses tumorigenesis in vivo. a. Transfected DLD-1 cells secrete WT FGF1 or R50E into culture medium. DLD-1 cells that
stably express WT FGF1 or R50E were generated. The WT FGF1 and R50E have a 6His-tag at the N-terminus. To detect FGF1 secreted from the
transfected cells, we analyzed the culture media by Western blotting with anti-6His antibodies. Mock-transfected cells were used as a control. As
a loading control, we ran the same samples in gel in parallel and stained the gel with Coomassie Brilliant Blue (CBB). b. Proliferation of DLD-1 cells in
the presence of 10% FCS. DLD-1 cells that secrete R50E grew in the medium that contains FCS in vitro at levels comparable to those of WT-FGF1
expressing cells or mock transfected cells. Statistical analysis was done by one-way ANOVA plus Tukey analysis. c. Proliferation of DLD-1 cells in the
absence of FCS. DLD-1 cells that secrete R50E grew in vitro in the medium without FCS at levels comparable to that of mock-transfected cells. Cells
that express WT FGF1 grew faster than mock-transfected and R50E expressing cells. Statistical analysis was done by one-way ANOVA plus Tukey
analysis. d. The growth curve of DLD-1 cells in vivo. WT FGF1 enhanced tumor growth in vivo, while R50E suppressed it (as shown by the growth
curve and the sizes of DLD-1 tumors removed at day 31). We injected the DLD-1 cells that secrete WT FGF1or R50E into nude mice (1 million cells/site)
at right and left inguinal regions (4 mice per group, 2 tumors/mouse). Mock-transfected cells were used as a control. Statistical analysis of tumor sizes
at Day 31 was done by t-test (n = 8 for mock and wt FGF, n = 7 for R50E). e. The sizes of tumors at Day 31. DLD-1 cells secreting wt FGF1 grew faster,
and cells secreting R50E slower, than mock-transfected cells (n = 8 for mock and wt FGF, n = 7 for R50E).
doi:10.1371/journal.pone.0057927.g001
The Dominant Negative FGF1 Mutant
PLOS ONE | www.plosone.org 4 February 2013 | Volume 8 | Issue 2 | e57927
induced by WT FGF1 (50 ng/ml). This indicates that R50E
suppresses newly sprouting vessels induced by WT FGF1.
R50E Suppresses Angiogenesis in Matrigel Plug Assays
The evaluation of angiogenesis influencing factors is ultimately
best made in vivo. We asked whether R50E is capable of
inhibiting WT FGF1 induced angiogenesis in vivo in a matrigel
plug assay. We injected matrigel plugs that contain WT FGF1
(1 mg/ml), R50E (1 mg/ml), or the mixture of WT FGF1 (1 mg/
ml) and excess R50E (50 mg/ml) subcutaneously into the back of
rat. We removed the plugs 10 days after injection and determined
the levels of angiogenesis by staining tissue sections for von
Willebrand factor, a marker for blood vessels. The number of
extended blood vessels was counted. We found that WT FGF1
markedly increased the number of blood vessels, whereas R50E
was defective in this function (Fig. 5). Excess R50E reduced the
number of blood vessels induced by WT FGF1. These findings
suggest that R50E suppresses angiogenesis induced by WT FGF1
in vivo.
R50E Suppresses Angiogenesis in Chick Embryo
Chorioallantoic Membrane (CAM) Model
CAM is another widely utilized in vivo system to study
angiogenesis and anti-angiogenesis and it is easier to quantify
angiogenesis in this assay than other assays. We placed saline- or
FGF- impregnated filter disks on blood vessels in avascular sections
of CAM (day 11) for 48 h to induce angiogenesis. The disks and
underlying CAM tissue (day 13) were then harvested. We scored
angiogenesis by counting vessel branches present in the CAM
tissue below the filter from digital images. We first determined
optimum dose of wt FGF1 for angiogenesis (Fig. 6a, 6b). Five ng/
ml of wt FGF1 was optimum. R50E (5 and 50 ng/ml) did not
induce angiogenesis. We tested if excess R50E (50 ng/ml)
suppresses angiogenesis induced by WT FGF1 (5 ng/ml). Notably,
excess R50E suppressed angiogenesis induced by WT FGF1
(Fig. 6c). This suggests that R50E shows an anti-angiogenic action
in this model as well. Since FGF1 binds to all known FGFRs
(FGFR1-4), R50E is expected to suppress FGFR signaling induced
by other members of the FGF family. We tested if R50E
suppresses angiogenesis induced by FGF2. We found that this is
the case: excess R50E suppressed angiogenesis induced by WT
FGF2 (Fig. 6c). The data suggest that R50E suppresses FGF1- and
FGF2-induced angiogenesis in the CAM model.
Taken together, R50E was defective in inducing angiogenesis,
and effectively suppressed angiogenesis in different in vitro and
Figure 2. R50E suppresses WT FGF1-induced endothelial cell
migration. Lower side of the filter in the modified Boyden chamber
was coated with fibronectin (10 mg/ml). The lower chamber was filled
with serum-free medium with WT FGF1 (5 ng/ml) or the mixture of WT
FGF1 and excess R50E (5 and 250 ng/ml, respectively). HUVECs were
plated on the filter and incubated for 6 h. Chemotaxed cells were
counted from the digital images of the stained cells. Data is shown as
means +/2 SE per field. Statistical analysis was done by one-way
ANOVA plus Tukey analysis.
doi:10.1371/journal.pone.0057927.g002
Figure 3. R50E suppresses WT FGF1- induced tube formation of
endothelial cells in vitro. Serum starved HUVECs were plated on
Matrigel-coated plates, and incubated in WT FGF1 (5 ng/ml) or the
mixture of WT FGF1 (5 ng/ml) and R50E (250 ng/ml) for 8 h. a.
Representative tube formation images are shown. Scale bar = 200 mm.
b. The number of branch points was counted per field from the digital
images. Data is shown as means +/2 SE. Statistical analysis was done by
one-way ANOVA plus Tukey analysis.
doi:10.1371/journal.pone.0057927.g003
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in vivo angiogenesis models. It is likely that R50E may indirectly
suppress tumorigenesis in vivo through suppressing angiogenesis.
Discussion
R50E is an Anti-angiogenic Agent
In the present study, we establish that R50E suppressed tumor
growth in vivo while WT FGF1 enhanced it using cancer cells that
stably express WT FGF1 or R50E. Since R50E showed little or no
effect on proliferation of cancer cells in vitro, we hypothesized that
R50E indirectly suppressed tumorigenesis through suppressing
angiogenesis. Excess R50E suppressed migration and tube
formation of HUVEC, and suppressed angiogenesis in aorta ring
assays and matrigel plug assays, suppressed angiogenesis in chick
embryo chorioallantoic membrane (CAM) assays, which is in-
duced by WT FGF1. Taken together, our results suggest that
R50E suppresses angiogenesis induced by FGF1 and thereby may
indirectly suppress tumorigenesis, in addition to its possible direct
effect on tumor cell proliferation in vivo. Furthermore, excess
R50E suppressed FGF2-induced angiogenesis in CAM assays,
suggesting that R50E may uniquely suppress signaling from other
members of the FGF family. We propose that R50E has potential
as an anti-cancer and anti-angiogenesis therapeutic agent (‘‘FGF1
decoy’’).
Potential Advantage of R50E Over Antibodies and Kinase
Inhibitors
Potential advantage of the FGF1 mutant R50E is that 1) R50E
is highly specific to FGFR1 compared to tyrosine kinase inhibitors,
which are selective rather than specific, and 2) R50E may have
higher affinity to FGFR1 (KD 10212 M) than antibodies to
FGFR1 (KD 1027 to 10211 M). Thus, we expect that much lower
dose may be required than antibodies to FGFR1. Also, 3) the large
size of antibodies results in poor tissue penetration [21], whereas
R50E could more fully interrogate a tumor mass. And 4) Currently
used target therapeutics (antibodies and kinase inhibitors) almost
always induce resistance after a while. This is partly due to point
mutations in antibody epitopes or inhibitor-binding sites. Cancer
cells obviously benefit from mutations that block the binding of
antagonists. We believe that R50E may not induce such mutations
Figure 4. R50E suppresses WT FGF1-induced angiogenesis in rat aortic ring. Isolated rat aortic ring was embedded in collagen gels in
DMEM containing WT FGF1 (50 ng/ml), R50E (50 ng/ml) or the mixture of WT FGF1 (50 ng/ml) and R50E (2500 ng/ml) and cultured for 10 days.
Representative phase contrast images of 3 independent experiments are shown. Scale bars, 100 mm.
doi:10.1371/journal.pone.0057927.g004
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in FGFR because R50E and FGF1 bind to FGFR exactly the same
way, and blocking binding of FGF1 (and other members of the
FGF family) to FGFR would not benefit cancer cells.
Can we Use Mutant Proteins as Therapeutics?
There is a precedent that a mutant of human protein was used
for human diseases. A mutant of human growth hormone (hGH)
has been used as an antagonist of GH receptor in the treatment of
acromegaly (Pegvisomant) [22]. The Gly-120 of hGH was mutated
to Arg (G120R) and this mutant was further modified by
poly(ethylene glycol) (PEG)-5000 to elongate half-life. Pegvisomant
prevents functional dimerization of hGH receptor by sterically
inhibiting conformational changes within the GHR dimers [22].
Pegvisomant is generally well tolerated with a safety profile similar
Figure 5. R50E suppresses angiogenesis in Matrigel plug assays in rat. Matrigel plug containing WT FGF1 (1 mg/ml), R50E (1 mg/ml) or the
mixture of WT FGF1 (1 mg/ml) and excess R50E (50 mg/ml) were injected subcutaneously into the back of rat, respectively. The plugs (n = 425) were
removed 10 days after injection and tissue sections were stained for von Willebrand factor, a blood vessel marker. a. Representative images are
shown. Scale bar = 50 mm. b. The number of extended blood vessels were counted under a light microscope. Data is shown as means +/2 SE.
Statistical analysis was done by one-way ANOVA plus Tukey analysis.
doi:10.1371/journal.pone.0057927.g005
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to that reported in clinical trials and can effectively reduce IGF1 in
patients with acromegaly refractory to conventional therapy [23].
We need to fully evaluate the potential of R50E as a therapeutic
agent in future studies. However, it is expected that R50E protein
may have a short half-life, and it may be rapidly cleared from
circulation. We will need to stabilize R50E and deliver it to the
tumor area to effectively suppress angiogenesis and tumorigenesis
in vivo. Interestingly, we discovered that direct integrin growth
factor interaction is also important for IGF1 [24,25] and NRG1
[19]. We propose that integrin-growth factor receptor crosstalk
through direct integrin-binding to growth factor and subsequent
ternary complex formation may be a common mechanism for the
crosstalk and integrin-growth factor interaction may be a novel
therapeutic target.
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